QT and TdP QT: An unreliable predictor of proarrhythmia

Acta Cardiologica

Volumn 63, Issue 1, 2008, Pages 1-7

  Hondeghem, Luc M ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Department of Pharmacology ^*  (Belgium)

Author keywords

Proarrhythmia; QT prolongation; Torsade de pointes (TdP); TRIaD; Ventricular fibrillation (VF)

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; SODIUM CHANNEL;

ACTION POTENTIAL; DRUG MECHANISM; ELECTROCARDIOGRAM; HEART MUSCLE REFRACTORY PERIOD; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; INCIDENCE; QRS COMPLEX; QT PROLONGATION; REVIEW; TACHYCARDIA; TORSADE DES POINTES;

ACTION POTENTIALS; ARRHYTHMIAS, CARDIAC; ELECTROCARDIOGRAPHY; HUMANS; LONG QT SYNDROME; TORSADES DE POINTES;

EID: 39349107214     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.63.1.2025324     Document Type: Review

References (23)

1. U.S. Food and Drug Administration. Docket No. 2004D0377: International conference on harmonisation; Draft Guidance on E14 Clinical Evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
2. Antzelevitch Antzelevitch C, Shimizu W, Yan GX, Sicouri S. Cellular basis for QT dispersion. J Electrocardiol 1998; 30: 168-75.
3. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
4. Vaughan Williams EM. Chapter 2: Classification of antiarrhythmic agents. In Vaughan Williams EM, ed. Antiarrhythmic Drugs. Handbook of Experimental Pharmacology Series (No 89). Berlin: Springer-Verlag, 1989: pp. 45-67.
5. Hondeghem LM, Katzung BG. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 1977; 472: 373-98.
6. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use-dependence. Circulation 1990; 81: 686-90.
7. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM, Pitt B, Schwartz PJ, Veltri EP, Waldo AL. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998; 81: 869-76.
8. Hondeghem L, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation 2001; 103: 2004-13.
9. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J, Volders PG, Vos MA. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004; 110: 2453-9.
10. ++ current. Circ Res 1989; 64: 977-90.
11. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2005; 2: 758-72.
12. Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006; 17: 337-40.
13. Hondeghem LM, Dujardin K, De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc Res 2001; 50: 345-53.
14. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96: 195-215.
15. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003; 89: 1363-72.
16. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
17. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007; 22: 39-43.
18. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993; 88: 1063-71.
19. Hondeghem LM, Lu HR, van Rossem K, De Clerck F. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 2003; 14: 287-94.
20. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
21. Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 2006; 316: 718-26.
22. Martin RL, Su Z, Limberis JT, Palmatier JD, Cowart MD, Cox BF, Gintant GA. In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience. J Cardiovasc Pharmacol 2006; 48: 199-206.
23. Hondeghem LM. Relative contributions of TRIaD and QT to proarrhythmia. J Cardiovasc Electrophysiol 2007; 18: 655-7.